Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Palandri, Francesca, Palumbo, Giuseppe Alberto, Bonifacio, Massimiliano, Tiribelli, Mario, Benevolo, Giulia, Martino, Bruno, Abruzzese, Elisabetta, D’Adda, Mariella, Polverelli, Nicola, Bergamaschi, Micaela, Tieghi, Alessia, Cavazzini, Francesco, Ibatici, Adalberto, Crugnola, Monica, Bosi, Costanza, Latagliata, Roberto, Di Veroli, Ambra, Scaffidi, Luigi, de Marchi, Federico, Cerqui, Elisa, Anaclerico, Barbara, De Matteis, Giovanna, Spinsanti, Marco, Sabattini, Elena, Catani, Lucia, Aversa, Franco, Di Raimondo, Francesco, Vitolo, Umberto, Lemoli, Roberto Massimo, Fanin, Renato, Merli, Francesco, Russo, Domenico, Cuneo, Antonio, Bacchi Reggiani, Maria Letizia, Cavo, Michele, Vianelli, Nicola, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668021/
https://www.ncbi.nlm.nih.gov/pubmed/29108288
http://dx.doi.org/10.18632/oncotarget.18674

Ejemplares similares

Ejemplares similares